Bristol-Myers Squibb (BMY) Reports In-Line Q2 EPS, Updates FY EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall Street rallies as Fed's Waller eases rate hike fears
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
Bristol-Myers Squibb Co. (BMY) PT Lowered to $61 at Leerink Partners
July 28, 2017 10:31 AM EDTLeerink Partners lowered its price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $61.00 (from $66.00) while maintaining a Outperform rating following the company's 2Q. BMY delivered in line earnings of 74c.
Analyst Seamus Fernandez now forecasts a 9% EPS growth in 2018-22E excluding Opdivo +... More
